Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis

BACKGROUND: The RxPONDER trial found that among breast cancer patients with estrogen receptor positive (ER+) breast cancer, 1-3 positive axillary nodes, and a recurrence score of ≤25, only pre-menopausal women benefitted from adjuvant chemoendocrine therapy; postmenopausal women with similar charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Stabellini, Nickolas, Cao, Lifen, Towe, Christopher W., Luo, Xun, Amin, Amanda L., Montero, Alberto J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165881/
https://www.ncbi.nlm.nih.gov/pubmed/37168373
http://dx.doi.org/10.3389/fonc.2023.1115208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165881/
https://www.ncbi.nlm.nih.gov/pubmed/37168373
http://dx.doi.org/10.3389/fonc.2023.1115208

Ejemplares similares